Jury Orders Medtronic to Pay $88M in First Covidien Hernia Mesh Trial

A federal jury has ordered Medtronic to pay $88 million in damages, marking the first case involving the company's Covidien hernia mesh product to reach trial and produce a verdict. The decision, handed down in 2026, represents a watershed moment in the years-long litigation surrounding the device, which has drawn scrutiny over its safety profile and the adequacy of warnings provided to patients and surgeons.

Covidien, now a division of Medtronic following the company's 2015 acquisition, manufactured hernia mesh products designed to reinforce tissue during abdominal wall repair surgery. Hernia mesh has become a standard tool in surgical practice, but a subset of these devices have been linked to complications including chronic pain, infection, and the need for revision surgeries to remove or replace the implant. Patients who experienced such complications have pursued legal claims against the manufacturer, alleging the company either knew or should have known about the risks and failed to adequately communicate them.

This particular case represents the first time a jury has weighed the evidence and rendered a judgment on the merits. The $88 million award reflects the jury's assessment of both compensatory damages—money intended to cover medical expenses, pain and suffering, and other harms—and potentially punitive damages designed to penalize the company for its conduct. The specific allegations and evidence presented at trial remain part of the court record, though the core dispute likely centered on whether the mesh design was defective, whether warnings were insufficient, or both.

The verdict carries weight beyond the single plaintiff who brought the case. Thousands of similar claims remain pending in courts across the country, many consolidated in multidistrict litigation. Defense lawyers and plaintiffs' attorneys alike will scrutinize how this jury evaluated the evidence, what arguments resonated, and what damages they deemed appropriate. For Medtronic, the judgment opens the door to a cascade of trials, each presenting the opportunity for similar or larger awards. For claimants still awaiting resolution, the verdict may strengthen their negotiating position in settlement discussions.

Medial device manufacturers operate in a heavily regulated environment, with the FDA overseeing product approval and ongoing safety monitoring. Yet regulatory clearance does not shield companies from product liability claims if evidence emerges that a device causes harm beyond what was disclosed or foreseeable. The hernia mesh litigation has raised questions about how thoroughly manufacturers tested their products, what adverse event data they possessed, and whether they communicated candidly with the medical community about known risks.

For patients who received Covidien hernia mesh and subsequently suffered complications, this verdict validates their claims that something went wrong—and that responsibility lies with the manufacturer. Many have endured chronic pain, multiple surgeries, and years of medical management. Some have had their mesh removed; others live with ongoing symptoms. The $88 million judgment does not undo their suffering, but it represents a legal acknowledgment that Medtronic bears liability for the harm.

The company has indicated it intends to defend itself vigorously in remaining cases and may pursue appeals in this matter. However, the precedent is now set. Future juries will know that at least one panel of their peers found Medtronic liable for hernia mesh injuries. That knowledge will shape how subsequent cases unfold, what settlement offers look like, and whether additional claimants decide to pursue litigation rather than accept a negotiated resolution. The landscape of this litigation has fundamentally shifted.